Compare AbbVie Inc (ABBV) vs Cloudflare Inc (NET) Price & Performance

AbbVie (ABBV) trades at $254.44, showing slight daily weakness but maintaining a bullish technical structure with strong institutional support. The company has consistently beaten earnings expectations in recent quarters, with Q1 2026 EPS of $2.65 exceeding the $2.59 estimate. Revenue growth is accelerating, reaching $61.16B in 2025, while the immunology portfolio (Skyrizi, Rinvoq) successfully offsets Humira declines. Analyst consensus remains strongly positive with 68% buy ratings and a $266.33 price target.

The outlook is constructive with robust pipeline developments and dividend growth, though elevated valuation multiples (P/E 124.83, P/B 245.29) and looming patent cliffs in the 2030s present risks. Net income margin compression from 20.38% in 2022 to 6.9% in 2025 requires monitoring, but strong cash generation ($19.03B operating cash flow) supports continued shareholder returns.

NET trades at $268.77, up 11% today after Scotiabank upgraded the stock citing AI growth potential. The stock shows strong bullish momentum with a consensus analyst rating of 'Buy' (70% of 40 analysts) and a price target of $246.58. Recent earnings beats and revenue growth to $2.17B in 2025 highlight operational strength, though negative net margins and high valuations (P/S 37.22) pose challenges. Technical indicators signal bullish trends with resistance near $262.

Outlook: Growth driven by AI infrastructure demand and strategic partnerships offers upside, but high valuation and lack of profitability increase risk. Investors should weigh robust revenue growth against margin pressures and competitive threats in the cloud sector.